Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses

被引：0

作者：

Lei, Ming ^{[1
]}

Janjigian, Yelena Y. ^{[2
,3
]}

Ajani, Jaffer A. ^{[4
]}

Moehler, Markus ^{[5
]}

Wang, Xuya ^{[1
]}

Shen, Lin ^{[6
]}

Garrido, Marcelo ^{[7
]}

Gallardo, Carlos ^{[8
]}

Yamaguchi, Kensei ^{[9
]}

Wyrwicz, Lucjan ^{[10
]}

Skoczylas, Tomasz ^{[11
]}

Bragagnoli, Arinilda ^{[12
]}

Liu, Tianshu ^{[13
]}

Tehfe, Mustapha ^{[14
]}

Elimova, Elena ^{[15
]}

Li, Mingshun ^{[1
]}

Poulart, Valerie ^{[1
]}

Wang, Yu ^{[1
]}

Doshi, Parul ^{[1
]}

Shitara., Kohei ^{[16
]}

机构：

[1] Bristol Myers Squibb, Princeton, NJ USA

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Weill Cornell Med Coll, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Johannes Gutenberg Univ Clin, Mainz, Germany

[6] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol,Minist Educ Beijing, Beijing, Peoples R China

[7] Pontificia Univ Catolica, Clin San Carlos Apoquindo, Santiago, Chile

[8] Fdn Arturo Lopez Perez, Santiago, Chile

[9] Canc Inst Hosp JFCR, Tokyo, Japan

[10] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland

[11] Med Univ Lublin, Klin Chirurg Ogolnej Gastroenterol & Nowotworow U, Lublin, Poland

[12] Fdn Pio Xii Hosp Canc Barretos, Barretos, Brazil

[13] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[14] CHU Montreal, Oncol Ctr, Montreal, PQ, Canada

[15] Princess Margaret Canc Ctr, Toronto, ON, Canada

[16] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT023

引用

页数：3

共 50 条

[1] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Janjigian, Y. Y.
Ajani, J. A.
Moehler, M.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Li, M.
Poulart, V.
Lei, M.
Kondo, K.
Shitara, K.
ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330
[2] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Moehler, M.
Shitara, K.
Garrido, M.
Salman, P.
Shen, L.
Wyrwicz, L.
Yamaguchi, K.
Skoczylas, T.
Campos Bragagnoli, A.
Liu, T.
Schenker, M.
Yanez, P.
Tehfe, M.
Poulart, V.
Cullen, D.
Lei, M.
Kondo, K.
Li, M.
Ajani, J. A.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
[3] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): expanded efficacy and safety data from CheckMate 649
Moehler, M.
Shitara, K.
Garrido, M.
Salman, P.
Shen, L.
Wyrwicz, L.
Yamaguchi, K.
Skoczylas, T.
Bragagnoli, Campos A.
Liu, T.
Schenker, M.
Yanez, P.
Tehfe, M.
Li, M.
Cullen, D.
Memaj, A.
Lei, M.
Xiao, H.
Janjigian, Y. Y.
Ajani, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 79 - 80
[4] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
Elimova, Elena
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649
Shitara, Kohei
Janjigian, Yelena Y.
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Silva, Arinilda
Bragagnoli, Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Soleymani, Samira
Lei, Ming
Kondo, Kaoru
Li, Mingshun
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[6] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Moehler, M.
Janjigian, Y. Y.
Shitara, K.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Bruges, R.
Cleary, J. M.
Karamouzis, M.
Soleymani, S.
Lei, M.
Amaya, Chanaga C.
Ajani, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
[7] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 306 - 306
[9] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
Moehler, Markus H.
Shitara, Kohei
Garrido, Marcelo
Salman, Pamela
Shen, Lin
Wyrwicz, Lucjan
Yamaguchi, Kensei
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Schenker, Michael
Yanez, Patricio Eduardo
Tehfe, Mustapha
Li, Mingshun
Cullen, Dana
Memaj, Arteid
Lei, Ming
Xiao, Hong
Janjigian, Yelena Y.
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Ruihua
Guo, Weijian
Qin, Shukui
Yang, Nong
Lu, Jianwei
Shitara, Kohei
Lei, Ming
Li, Mingshun
Bao, Nicole
Chen, Tian
Liu, Tianshu
CANCER RESEARCH, 2021, 81 (13)

← 1 2 3 4 5 →